Jiangsu Vcare Selected Among "Top 100 China Pharma Innovation Seed Enterprises 2024"
Published Time:
2024-10-23 17:49
Source:
Recently, the "Top 100 China Pharma Innovation Seed Enterprises 2024" list was released, withJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) ranked in the second tier. This list, compiled by a non-governmental organization, evaluates enterprises based on innovation foundation, process, and outcomes—using patent data, clinical trial data, etc.—selected from over 5,000 Chinese pharmaceutical companies.
Following its inclusion in the 2022 list, Jiangsu Vcare's reappearance in 2024 reflects the industry's full recognition of its innovation strength. Since inception, Jiangsu Vcare has prioritized innovation as its core driver, continuously advancing technological transformation. In recent years, the company has significantly increased R&D investment, recruited top talent, and procured internationally advanced equipment, demonstrating unwavering commitment to innovation.
Jiangsu Vcare has established cutting-edge technology platforms—including AI molecular generation, drug screening, crystal/salt form selection, and novel formulations—focusing precisely on therapeutic areas such as cardiovascular, oncology, inflammation, and autoimmune diseases. Currently, it has5 clinical-stage Class I innovative drug projectsand over10 preclinical projectsunder development, forming a diversified, high-potential R&D pipeline.
Moving forward, Jiangsu Vcare will adhere to its innovation-driven and globalized strategy, targeting frontier technologies and unmet clinical needs to develop breakthrough therapeutics, contributing "Vcare Power" to global health.
Related News
20
2023
/
01
I. Corporate Development and Infrastructure ① Wholly-owned subsidiary Nanjing Vcare successfully acquired Hubei Tianshu Pharmaceutical Co., Ltd. ② CDMO Business Technology Center completed and operational. ③ Established new technology platform laboratories. ④ Built a new Innovative Drug Synthesis Technology Center.
View Details
27
2022
/
12
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed a Series B financing round exceeding CNY 200 million,which were led by Changjiang Venture Capital ,with participation from Hongcheng Capital and Hangzhou Huadian Investment, and continued support from Yangtze River Industry Group and SDIC Capital. The raised funds will be used to accelerate the clinical development of the company's core innovative drug products and the construction of its CDMO industrial base.
View Details
19
2022
/
05
Recently, Vicagrel capsules, a Class 1 novel antiplatelet agent developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare), received Clinical Trial Approval from the NMPA for the target indication of minor ischemic stroke (MIS) or transient ischemic attack (TIA). The related Phase II clinical trial is set to begin shortly.
View Details
06
2022
/
05
Jiangsu Vcare Closes Series A2 Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series A2 financing round. This marks the successful closing of the company’s Series A financing, bringing the total Series A funding to nearly $60 million. This round was led by existing investor SDIC Capital, with co-investment from Yangtze River Industry Group. The proceeds will primarily support the R&D of innovative drug candidates as well as the construction of R&D and production bases for its CDMO business.
View Details
22
2021
/
11
On November 19, 2021, the first clinical trial participant was dosed with VC005 tablets, a highly selective JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Jiangsu Vcare). The dosing was completed at the Phase I Clinical Research Center of the First Hospital of Jilin University, and the participant has now successfully completed the safety observation period.
View Details
18
2021
/
08
Initiation Meeting of FDA-FE Clinical Study of Vicagrel Capsules
On August 18, the kick-off meeting of the FDA-FE clinical study of Vicagrel Capsules, a Class I new drug of Jiangsu Vcare Pharmatech Co., Ltd. (Jaingsu Vcare), was held at the Phase I Clinical Research Center of the First Hospital of Jilin University. This marks the official launch of the FDA clinical study of Vicagrel in the United States and the supporting Phase III clinical study in China.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn